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Patient-Reported Outcomes in Relation to Continuously Monitored
Rhythm Before and During 2 Years After Atrial Fibrillation Ablation
Using a Disease-Speciﬁc and a Generic Instrument
Anna Bj€orkenheim, MD; Axel Brandes, MD, DMSc; Anders Magnuson, BSc; Alexander Chemnitz, BSc; Nils Edvardsson, MD, PhD;
Dritan Poci, MD, PhD
Background-—Atrial ﬁbrillation (AF) ablation improves patient-reported outcomes, irrespective of mode of intermittent rhythm
monitoring. We evaluated the use of an AF-speciﬁc and a generic patient-reported outcomes instrument during continuous rhythm
monitoring 2 years after AF ablation.
Methods and Results-—Fifty-four patients completed the generic 36-Item Short-Form Health Survey and the AF-speciﬁc AF6
questionnaires before and 6, 12, and 24 months after AF ablation. All patients underwent continuous ECG monitoring via an
implantable loop recorder. The generic patient-reported outcomes scores were compared with those of a Swedish age- and sex-
matched population. After ablation, both summary scores reached normative levels at 24 months, while role-physical and vitality
remained lower than norms. Responders to ablation (AF burden <0.5%) reached the norms in all individual 36-Item Short-Form
Health Survey domains, while nonresponders (AF burden >0.5%) reached norms only in social functioning and mental component
summary. All AF6 items and the sum score showed moderate to large improvement in both responders and nonresponders,
although responders showed signiﬁcantly greater improvement in all items except item 1 from before to 24 months after ablation.
Higher AF burden was independently associated with poorer physical component summary and AF6 sum score.
Conclusions-—The AF-speciﬁc AF6 questionnaire was more sensitive to changes related to AF burden than the generic 36-Item
Short-Form Health Survey. Patients improved as documented by both instruments, but a higher AF burden after ablation was
associated with poorer AF-speciﬁc patient-reported outcomes and poorer generic physical but not mental health. Our results
support the use of an AF-speciﬁc instrument, alone or in combination with a generic instrument, to assess the effect of ablation.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT00697359. ( J Am Heart Assoc. 2018;7:
e008362. DOI: 10.1161/JAHA.117.008362.)
Key Words: atrial ﬁbrillation • catheter ablation • quality of life
A trial ﬁbrillation (AF) frequently causes symptoms thathave a negative impact on health-related quality of life
(HRQoL).1,2 In addition to symptoms, side effects of medica-
tions and comorbidities can reduce HRQoL in AF patients.3
Catheter ablation of AF is an increasingly used treatment
for patients with symptomatic paroxysmal and persistent AF
who have failed antiarrhythmic drug therapy and in selected
patients with paroxysmal AF as ﬁrst-line therapy.4 Success of
AF ablation is primarily reported as freedom from AF based on
intermittent rhythm monitoring,5 although the main goal of AF
intervention is a reduction of symptoms and improvement of
HRQoL4,6 (ie, improvement of patient-reported outcomes
[PROs]). AF ablation has been shown to improve PROs in
patients with AF, predominantly using generic instruments
during intermittent rhythm monitoring.7 Occasionally, the
resulting HRQoL was compared with that of the general
population.7,8
AF-speciﬁc instruments have been developed, variously
well validated and used to different extents in order to
increase the sensitivity to detect changes in PROs related
to AF, but little is known about their performance in relation to
long-term continuous rhythm monitoring.
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The aim of this study was to (1) evaluate effects of AF
ablation on AF-speciﬁc and generic PROs; and (2) assess the
association between the AF-speciﬁc and the generic PROs
and the AF burden estimated by continuous rhythm monitor-
ing over a period of 2 years after ablation. The generic HRQoL
of a Swedish age- and sex-matched population was used as
reference.
Methods
Patients
Patients scheduled for AF ablation were enrolled at 2 Scandi-
navian university hospitals between April 2009 and January
2013. All patients gave their written informed consent, and the
study protocol was approved by the Regional Ethical Review
Board in Uppsala and the Regional Scientiﬁc Ethical Commit-
tees for Southern Denmark and complied with the Declaration
of Helsinki. All patients completed the generic 36-Item Short-
Form Health Survey (SF-36) questionnaire (version 1)9 and the
AF-speciﬁc AF6 questionnaire10 before and 6, 12, and
24 months after ablation. After instruction, the patients
completed the questionnaires before ECGs were recorded
and without interaction from physicians or nurses.
The corresponding author has full access to all study data
and takes responsibility for their integrity and the data analysis.
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Generic HRQoL Instrument and Norm Data
SF-36 consists of 36 items assessing 8 domains reﬂecting
physical and mental health aspects: physical functioning, role-
physical, bodily pain, general health, vitality, social functioning,
role-emotional, and mental health. Domain scores range from 0
to 100, with higher values indicating better HRQoL. The 8
domains generate 2 summary measures: the physical compo-
nent summary (PCS) and the mental component summary
(MCS) scores.11 PCS andMCS are calculated using norm-based
scoring with a mean of 50 and a value above 50 indicating
better HRQoL than the general Swedish population. In the
Swedish validation of SF-36, internal consistency reliability
estimated (Cronbach a) for the 8 domains ranged between 0.79
(role-emotional) and 0.93 (bodily pain).9
The SF-36 proﬁle was compared with a general population
sample randomly selected from the Swedish SF-36 normative
database (n=8930; response rate 68%).9 The normative
sample (validated in Sweden 1991–1992) was matched for
sex and age and comprised 742 people (453 males) with a
mean age of 56.9 years (9.3 SD).
AF-Speciﬁc Instrument
AF6 is a validated AF-speciﬁc PRO instrument10 tested for
clinical responsiveness,12 with a recall period of 7 days. This
6-item questionnaire includes item 1 “breathing difﬁculties at
rest,” item 2 “breathing difﬁculties upon exertion,” item 3
“limitations in day-to-day life due to AF,” item 4 “feeling of
discomfort due to AF,” item 5 “tiredness due to AF,” and item 6
“worry/anxiety due to AF.” A score of 0 (no symptoms) to 10
(severe symptoms) is recorded for each item, and all scores are
added to give a single sum score of 0 to 60, with higher values
reﬂecting more severe AF-related symptoms. The internal
consistency of the 6 items measured using Cronbach a was
0.82, 0.88, 0.19, 0.04, 0.39, and 0.93, respectively.10
Implantable Loop Recorder and Catheter Ablation
Patients were implanted with an implantable loop recorder
(Reveal XT; Medtronic Inc, Minneapolis, MN) at least 2 weeks
before the ablation. This remained active for a minimum of
24 months after ablation. The AF detection algorithm classiﬁes
the heart rhythm as AF when the R-R intervals within a 2-minute
interval show uncorrelated irregularity.13 The AF burden was
calculated as the percentage of time in AF between each follow-
up visit based on manually adjudicated AF episodes.14 In
addition, we used the only published AF burden cut-off limit
after AF ablation of <0.5% at each scheduled visit in order to
classify patients as responders or nonresponders.14,15 The
catheter ablation consisted of circumferential radiofrequency
lines around each pair of pulmonary veins.14 Reablation was
permitted at the investigator’s discretion.
Statistical Analyses
Categorical variables are presented as percentages and
continuous variables as meanSD or median and interquartile
Clinical Perspective
What Is New?
• Patients with a low atrial ﬁbrillation (AF) burden (<0.5%)
reached age- and sex-matched norms in all individual
36-Item Short-Form Health Survey domains, while patients
with an AF burden (>0.5%) reached norms only in social
functioning and mental component summary.
• The AF-speciﬁc AF6 showed moderate to large improvement
in all patients, irrespective of AF burden, but the improve-
ment was greater in patients with an AF burden <0.5%.
• Higher AF burden was independently associated with worse
physical health and worse AF6 sum score.
What Are the Clinical Implications?
• The AF6 was more sensitive to changes related to AF
burden than the 36-Item Short-Form Health Survey, which
supports the use of an AF-speciﬁc instrument to assess the
effect of AF ablation.
DOI: 10.1161/JAHA.117.008362 Journal of the American Heart Association 2
PRO Instruments and AF Ablation Bj€orkenheim et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 26, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
range where appropriate. Unpaired t tests were used for
comparison of SF-36 domains between patients versus
norms. The linear mixed model for repeated measurement
with unstructured covariance was used to compare SF-36 and
AF6 mean scores over time: at baseline, 6, 12, and
24 months after ablation, in all patients and in responders
and nonresponders. Linear regression was used to evaluate
potential prognostic variables for the PCS, MCS, and AF6 sum
score at 24 months. The potential prognostic variables were
age, sex, persistent AF, AF burden 3 to 24 months after
ablation, hypertension, previous stroke/transient ischemic
attack, left ventricular ejection fraction, left atrial diameter,
antiarrhythmic drugs before ablation, and body mass index.
The AF burden was evaluated on a log linear scale, and age,
left ventricular ejection fraction, and left atrial diameter were
evaluated on a continuous scale, while the remaining variables
were categorical. Body mass index was categorized as normal
weight (<25 kg/m2), overweight (25 to <30 kg/m2), and
obese (≥30 kg/m2) using the World Health Organization
standard, and age was evaluated both as continuous and
categorical variables as ≤65 or >65 years. All regression
analyses were adjusted for age and sex as it has been shown
that HRQoL is associated with age and sex,16 which could be
confounders in the study. All potential prognostic variables
were further included in a multiple linear regression to identify
independent prognostic variables for the PROs. In the same
way, linear regression was used to evaluate the change in PRO
scores from baseline to 24 months adjusted for the baseline
score of the outcome. The magnitude of differences between
patients and norms and patients before and after ablation was
determined by calculation of effect sizes (ESs). ES was
estimated by calculating the mean difference, divided by the
pooled SD (Cohen’s d). ES was interpreted according to
standard criteria: trivial (<0.20), small (0.20–0.49), moderate
(0.50–0.79), and large (≥0.80).17 A P value of <0.05 was
considered statistically signiﬁcant. To account for multiple
testing, Bonferroni correction was performed for the number
of tests applied in each analysis. Statistical analyses were
done using SPSS version 22 (IBM, Armonk, NY); some
graphical presentations used Excel 2010 (Microsoft Corpora-
tion, Redmond, WA).
Results
Baseline Demographics
Clinical characteristics are shown in Table 1. The mean age
was 579 years, and there was a majority of men (60%).
Fifty-four patients completed the 24-month follow-up. All
answered questionnaires were fully completed, and the
response rate was 100% before ablation and 98%, 89%, and
98% at 6, 12, and 24 months after ablation, respectively.
Generic HRQoL Before Ablation in Relation to the
General Population
Seven of the 8 SF-36 domains and summary scores showed
statistically signiﬁcantly lower values as compared with sex-
and age-matched population norms (Table 2 and Figure). The
mean difference in summary scores between patients and
norms corresponded to moderate ESs (PCS 0.64 and MCS
0.65). The effect sizes for the domains varied between small
(general health 0.41) and large (role-physical 1.1) and were
interpreted as small to moderate in most domains but large in
vitality and role-physical.
Change in Generic HRQoL After Ablation
Four of the 8 SF-36 domains and the summary scores
improved signiﬁcantly 2 years after ablation (Table 3). The
effect sizes were moderate for the domains role-physical and
social functioning but were otherwise small. The improvement
occurred mainly during the ﬁrst 6 months after ablation. The
mean of the summary scores, physical functioning, general
Table 1. Baseline Patient Characteristics
n=57
Male sex 34 (60%)
Age, y (meanSD) 579
BMI (meanSD) 295
Paroxysmal AF 50 (88%)
Months from first AF episode (median [IQR]) 57 (IQR 36–120)
Concomitant cardiovascular disease
Heart failure 2 (4%)
Hypertension 24 (42%)
Diabetes mellitus 2 (4%)
Coronary artery disease 1 (2%)
Valvular heart disease 1 (2%)
Stroke/TIA 8 (14%)
CHA2DS2-VASc scores
0 15 (26%)
1 20 (35%)
≥2 22 (39%)
Medications
b-Blockers 37 (65%)
Class I AAD 16 (28%)
Class III AAD 16 (28%)
Values are n (%), meanSD, or median (IQR). AAD indicates antiarrhythmic drugs; AF,
atrial ﬁbrillation; BMI, body mass index; CHA2DS2-VASc, congestive heart failure,
hypertension, age ≥65 or 75 years, diabetes mellitus, prior stroke/transient ischemic
attack, vascular disease, female sex; IQR, interquartile range; TIA, transient ischemic
attack.
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health, social functioning, role-emotional, and mental health
did not differ signiﬁcantly from that of the general population
at 24 months after ablation (Table 2), but the patients scored
slightly but signiﬁcantly lower than norms on role-physical and
vitality.
Change in Generic HRQoL in Responders and
Nonresponders
There were no signiﬁcant differences in the SF-36 domains
between subsequent responders and nonresponders before
ablation. Responders showed statistically signiﬁcantly
improved scores 2 years after ablation in physical function-
ing, role-physical, and PCS. The effect sizes were large in
physical functioning (0.86), role-physical (0.83), and role-
emotional (0.90), and moderate in general health (0.55),
vitality (0.54), social functioning (0.63), mental health (0.53),
and both summary scores (PCS 0.63 and MCS 0.64). The
responders reached the HRQoL of general population norms
in all domains and both summary scores. The nonresponders
showed signiﬁcant improvement in role-physical and social
functioning, in particular role-physical, where the ES was
moderate (0.58). However, nonresponders did not reach the
HRQoL of general population norms except in social
functioning and MCS. Responders showed signiﬁcantly
greater improvement in physical functioning and PCS than
nonresponders from before to 2 years after ablation
(Table 3).
Change in AF-Speciﬁc AF6 in Responders and
Nonresponders
All items and the sum score showed statistically signiﬁcant
improvement at 24 months after ablation, with moderate to
large ESs (Table 3). Before ablation, item 1, “breathing
difﬁculties at rest,” scored signiﬁcantly lower in subsequent
responders than nonresponders (P=0.01), while there were no
signiﬁcant differences in the other items or the AF6 sum
score. In responders, 5 items and the AF6 sum score showed
statistically signiﬁcant improvement, all with large ESs (ES
1.0–1.7). The only item not to reach statistical signiﬁcance,
item 1, still had a moderate ES of 0.58. All items and the AF6
sum score improved signiﬁcantly in nonresponders; item 2,
“breathing difﬁculities upon exertion,” showed a large ES
(0.84), and all others moderate ESs (ES 0.50–0.75). Respon-
ders showed signiﬁcantly greater improvement in all items
0 
20 
40 
60 
80 
100 
PF RP BP GH VT SF RE MH PCS MCS 
Patients before ablation 
Patients 24 months after ablation 
Norms 
Figure. Thirty-six-Item Short-Form Health Survey domain and summary scores before and 24* months after AF ablation compared with
Swedish age- and sex-matched population norms (n=742). BP indicates bodily pain; GH, general health; MCS, mental component summary; MH,
mental health; PCS, physical component summary; PF, physical functioning; RE, role-emotional; RP, role-physical; SF, social functioning; VT,
vitality. *Data from 1 patient are missing.
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except items 1 and 6 than nonresponders from before to
2 years after ablation (Table 3).
Prognostic Variables for AF6 Sum Score, PCS,
and MCS 24 Months After Ablation
Higher AF burden 3 to 24 months after ablation was
signiﬁcantly associated with a higher AF6 sum score,
indicating more severe AF-related symptoms, and a larger
increase in the AF6 sum score from baseline (Table 4), both
adjusted for age and sex as well as for all variables. Moreover,
the AF6 sum score increased 11.5 (95% conﬁdence interval,
4.3%–18.7%) points with every log unit increase in AF burden,
adjusted for all variables.
Higher AF burden after ablation and obesity, adjusted for
age and sex, were signiﬁcantly associated with lower PCS
(Table 5). The AF burden was still associated with lower PCS
when adjusted for all variables. Higher AF burden was also
signiﬁcantly associated with a negative change in PCS from
baseline adjusted for all variables. Persistent AF before
ablation was signiﬁcantly associated with lower MCS
24 months after ablation, adjusted for age and sex as well
as adjusted for all variables. Persistent AF was signiﬁcantly
associated with a negative change in MCS from baseline when
adjusted for all variables (Table 5). Higher age was associated
with higher MCS when adjusted for all variables.
Discussion
Main Findings
The generic HRQoL improved during the 2-year follow-up after
AF ablation with the greatest improvement during the ﬁrst
6 months after ablation. The physical and mental summary
scores reached normative levels 24 months after ablation.
The AF-speciﬁc instrument AF6 was more sensitive to
changes in PROs than the generic SF-36 as the AF6 detected
improvement in both responders and nonresponders to AF
ablation, although the improvement was greater in respon-
ders. A higher AF burden was associated with poorer generic
physical and AF-speciﬁc PROs.
Table 4. Linear Regression With Outcome AF6 Sum Score at 24 Months and Outcome AF6 Sum Change From Baseline to
24 Months by Demographic and Clinical Characteristics in 53 Patients
AF6 Sum Score at 24 Mo Change in AF6 Sum Score Baseline to 24 Mo
Adjusted for Age and Sex Adjusted for All Variables Adjusted for Age and Sex
Adjusted for
All Variables
b (95% CI) P Value b (95% CI) P Value b (95% CI) P Value b (95% CI) P Value
AF burden 3–24
mo, log
scale per unit
10.7 (4.7–16.6) 0.001* 11.5 (4.3– 18.7) 0.003* 10.5 (4.7–16.3) 0.001* 11.4 (4.3–18.5) 0.002*
Sex, female 2.2 (6.3 to 10.8) 0.60 0.2 (8.9 to 8.6) 0.97 0.6 (7.8 to 9.1) 0.88 1.0 (9.7 to 7.6) 0.81
Age (per y) 0.2 (0.2 to 0.6) 0.38 0.1 (0.4 to 0.6) 0.66 0.2 (0.2 to 0.6) 0.35 0.1 (0.3 to 0.6) 0.54
Age >65 y 1.3 (8.3 to 10.9) 0.79 3.6 (6.0 to 13.2) 0.45
BMI
<25 Ref. Ref. Ref. Ref.
25 to <30 5.1 (16.8 to 6.6) 0.38 1.4 (14.0 to 11.2) 0.82 8.7 (20.5 to 3.2) 0.15 3.6 (16.4 to 9.1) 0.56
≥30 2.7 (9.3 to 14.6) 0.66 3.4 (10.0 to 16.8) 0.61 1.7 (14.0 to 10.6) 0.79 1.1 (12.5 to 14.6) 0.87
Persistent AF 1.0 (11.6 to 13.6) 0.88 5.6 (7.2 to 18.4) 0.38 0.9 (11.3 to 13.2) 0.88 5.5 (7.1 to 18.1) 0.38
Hypertension 0.1 (8.7 to 9.0) 0.97 2.2 (6.5 to 10.9) 0.61 0.5 (9.2 to 8.1) 0.90 1.2 (7.4 to 9.9) 0.77
Previous
stroke/TIA
0.9 (12.4 to 10.6) 0.88 5.7 (17.5 to 6.1) 0.34 0.3 (11.5 to 10.9) 0.96 5.7 (17.3 to 6.0) 0.33
AAD 5.2 (13.3 to 2.8) 0.20 4.9 (13.1 to 3.3) 0.24 2.5 (11.2 to 6.2) 0.57 1.7 (10.8 to 7.3) 0.70
LVEF, per % 0.0 (0.8 to 0.7) 0.95 0.2 (0.9 to 0.6) 0.63 0.0 (0.7 to 0.7) 0.97 0.1 (0.9 to 0.6) 0.72
Left atrial
diameter,
per mm
2.6 (3.3 to 8.6) 0.38 1.0 (7.7 to 5.6) 0.76 1.4 (4.6 to 7.4) 0.64 1.8 (8.4 to 4.9) 0.60
Positive regression coefﬁcient b indicates higher (worse) AF6 sum score in exposed category compared with reference or per 1 unit increase in continuous variables log AF burden, age per
year, LVEF, and left atrial diameter. AF6 sum score of 0 to 60. AAD indicates antiarrhythmic drugs; AF, atrial ﬁbrillation; BMI, body mass index; CI, conﬁdence interval; LVEF, left ventricular
ejection fraction; TIA, transient ischemic attack.
*Signiﬁcant results (P<0.05).
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Improvement of PROs Following AF Ablation
The greatest impairment in HRQoL before ablation measured
by SF-36 was seen in the role-physical and vitality domains,
which indicates that patients experienced problems with daily
activities as well as energy and fatigue, which is in line with a
study by Wokhlu et al in 323 patients undergoing AF
ablation.18 The same domains also showed the greatest
improvement from before ablation to 24 months after abla-
tion but were still lower in patients than in norms at the end of
follow-up. This is in contrast to the study of Wokhlu et al in
which all SF-36 domains reached norm values, but their
norms were not matched for age and sex and they used the
same mean score for every domain for norms, which may
have affected their results. Nevertheless, in both studies both
the physical and mental summary scores and domains
representing mental health and social aspects of life reached
normative levels after ablation. This is consistent with a
recent meta-analysis that also showed that AF ablation is
associated with a signiﬁcant increase in both PCS and MCS.19
All items in the AF-speciﬁc instrument AF6 improved after
ablation, with large ESs in items corresponding to limitations
in day-to-day life, feelings of discomfort and tiredness
because of AF, as did the AF6 sum score, which is consistent
with previous studies. Wokhlu et al used the not yet validated
Mayo AF-Speciﬁc Symptom Inventory and showed signiﬁcant
improvement in 10 of 12 symptoms 2 years after ablation.18
Raine et al used a validated AF-speciﬁc instrument, the Atrial
Fibrillation Effect on Quality-of-Life, before and 3 months after
AF ablation and found a signiﬁcant improvement only in
patients without AF recurrence.20
Relationship Between AF Burden and PROs After
Ablation
Responders improved to the level of general population norms
in all SF-36 domains while nonresponders only reached norm
level in social functioning and MCS. When using the AF-
speciﬁc instrument AF6, both responders and nonresponders
showed moderate to large improvement 24 months after
ablation, even though the improvement was signiﬁcantly
larger in all AF6 items except items 1 and 6 in responders.
Furthermore, a higher AF burden after ablation was indepen-
dently associated with poorer physical health and more
severe AF-related symptoms. There are several possible
explanations for these ﬁndings, the most likely one being
that reduction of the AF burden brought improvement in PROs
in nonresponders even though AF was not entirely eliminated.
Mantovan et al found an improvement of generic HRQoL with
SF-36 both in patients with and without arrhythmia recurrence
at 12 months after ablation, even though arrhythmia recur-
rence caused less improvement of the summary scores.7 A
Table 5. Linear Regression With Outcome PCS and MCS Scores at 24 Months and Outcome PCS and MCS Change From Baseline
to 24 Months by Demographic and Clinical Characteristics in 53 Patients
PCS/MCS at 24 Mo Change in PCS/MCS From Baseline to 24 Mo
Adjusted for
Age and Sex
Adjusted for
All Variables
Adjusted for
Age and Sex
Adjusted for
All Variables
b (95% CI) P Value b (95% CI) P Value b (95% CI) P Value b (95% CI) P Value
PCS
AF burden 3–24
mo, log scale
per unit
5.0 (9.7 to 0.3) 0.04* 7.0 (12.2 to 1.7) 0.01* 5.9 (9.8 to 2.0) 0.004* 6.7 (11.4
to 2.0)
0.006*
Age (per y) 0.1 (0.5 to 0.2) 0.45 0.0 (0.3 to 0.4) 0.78 0.0 (0.3 to 0.2) 0.75 0.1 (0.3 to 0.4) 0.72
Age >65 y 2.9 (9.9 to 4.1) 0.41 2.1 (8.1 to 3.9) 0.49
Persistent AF 5.7 (14.9 to 3.4) 0.21 5.9 (15.3 to 3.4) 0.21 4.1 (12.0 to 3.8) 0.30 5.3 (13.6
to 3.1)
0.21
MCS
AF burden 3–24
mo, log scale
per unit
3.4 (8.3 to 1.5) 0.17 2.3 (7.8 to 3.2) 0.41 3.8 (8.3 to 0.6) 0.09 3.0 (8.3
to 2.3)
0.26
Age (per y) 0.1 (0.2 to 0.5) 0.39 0.4 (0.0 to 0.8) 0.03* 0.0 (0.4 to 0.3) 0.78 0.2 (0.2 to 0.6) 0.37
Age >65 y 0.6 (6.5 to 7.7) 0.87 2.8 (9.5 to 4.0) 0.41
Persistent AF 9.8 (18.7 to 0.9) 0.03* 10.1 (20.0 to 0.3) 0.04* 7.8 (16.2 to 0.5) 0.06 9.4 (18.8 to 0.1) 0.048*
Negative regression coefﬁcient b indicates lower (worse) PCS/MCS scores in exposed category compared with reference, or per 1 unit increase in continuous variables log AF burden, age,
LVEF, and left atrial diameter. AF indicates atrial ﬁbrillation; CI, conﬁdence interval; LVEF, left ventricular ejection fraction; MCS, mental component summary; PCS, physical component
summary.
*Signiﬁcant results (P<0.05).
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subgroup analysis showed that patients with AF up to
1.3 hours per month measured by intermittent rhythm
monitoring improved in all SF-36 domains, while patients
with AF 4.8 to 720 hours per month did not or had
deteriorated at 12 months after ablation.
The improvement in nonresponders may, at least in part, be
because of diminished perception of the AF episodes after
ablation, and this may have reduced symptoms enough to give
meaningful relief, both in generic and particularly in
AF-speciﬁc PROs.21 Furthermore, preprocedural anxiety may
have caused lower scores before the ablation and may have
overestimated the changes in PROs, but since the question-
naires were completed at least 1 month before the procedure,
this is less likely. Patients undergoing AF ablation are often
highly symptomatic, and improvement may also be the result of
an expectancy effect. However, in our study, the improvement
in PROs at 6 months after ablation was maintained at
24 months, rendering an expectancy effect unlikely. Moreover,
it is also possible that the closer follow-up in a clinical study per
se could reduce anxiety and increase psychological well-being.
The implantable loop recorder continuously monitored and
detected both symptomatic and asymptomatic AF episodes
that were then manually adjudicated before being entered into
the AF burden. This full knowledge of the AF burden is the
greatest strength of our study, as previous studies investi-
gating PROs in relation to rhythm after AF ablation have used
intermittent monitoring of different intensity to determine
ablation success. We believe that rhythm monitoring is an
important additional aspect in order to correctly understand
the effects on PROs. Intermittent monitoring may have
contributed to the conﬂicting results reported by these
studies, with some reporting improvement in generic PROs
regardless of AF recurrences7,18,22 and others improvement
only in patients who are classiﬁed as free of AF
recurrences.8,20 The recently published 5-year follow-up of
MANTRA-PAF (The Medical Antiarrhythmic Treatment or
Radiofrequency Ablation in Paroxysmal Atrial Fibrillation) trial
showed that the improvement in generic HRQoL measured by
SF-36 seen at 2 years after ablation remained and was similar
in patients who underwent AF ablation and pharmacological
rhythm control in spite of more AF recurrences in the
latter group.23,24 However, previous studies that did
include AF-speciﬁc instruments (Mayo AF-Speciﬁc Symptom
Inventory, Atrial Fibrillation Effect on Quality-of-Life, and
University of Toronto atrial ﬁbrillation severity scale) showed
that ablation outcome is most often correlated with
AF-speciﬁc PROs.18,20,22
Interestingly, we found no signiﬁcant association between
AF burden and mental health after ablation, but persistent AF
and younger age before ablation were both independently
associated with poorer mental health. This is in line with a
previous study reporting that younger patients had poorer
mental health than older patients and may beneﬁt more from
treatment.3
Generic and AF-Speciﬁc PROs: Similarities and
Differences
Generic instruments measure general health and functioning
and are inﬂuenced by patient demographics and comorbidity,
while AF-speciﬁc questionnaires were developed speciﬁcally
to measure AF-related PROs. Our results suggest that the AF6
is more sensitive than SF-36 in capturing more components of
AF, which is in line with previous studies using other
AF-speciﬁc PRO instruments.18,20,22 The potential for comor-
bidities to impact PRO scores further points to the need for
AF-speciﬁc instruments when studying AF interventions. We
believe that assessment of PROs after AF ablation should
always include an AF-speciﬁc instrument. The main advan-
tages of the AF6 instrument are that it is validated for AF
patients and straightforward and simple to use and can easily
be included in a routine clinical visit. The AF6 item 1
“breathing difﬁculities at rest” was lower in responders than
nonresponders even before ablation, implying that this is an
important symptom that could possibly indicate a more
severe disease with lower success rates after ablation.
Limitations
The study population was small and did not have a
randomized control group but was followed in great detail
for 2 years after ablation. Because of the low power, we have
likely failed to detect some existing associations, but the
signiﬁcant predictors we have found are probably valid. The
AF6 and the SF-36 had different recall periods, which may
have inﬂuenced the results. The latest available national norm
data, used in our study, were validated in 1991–1992, and the
HRQoL of the general population may have changed since
then. The AF6 was validated in symptomatic patients
undergoing direct-current cardioversion for short-lasting per-
sistent AF, while patients in the present study had paroxysmal
and persistent AF.
Conclusions
Patients improved after AF ablation as documented by a
generic and an AF-speciﬁc instrument, but the AF6 was more
sensitive to changes in PROs related to AF burden. However, a
higher AF burden after ablation was associated with poorer
generic physical health and worse AF-speciﬁc PRO, but not
with mental health. The arbitrary AF burden cut-off limit of
0.5% was not a clinically meaningful efﬁcacy end point, when
the effect on PROs was taken into consideration. Focusing on
AF-speciﬁc symptoms and their impact on HRQoL, both in
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selection of ablation candidates and as an outcome measure
after AF ablation, is reasonable as symptoms and impaired
HRQoL are what bring the patients to the physician and are
currently the main indications for AF ablation.
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